Professor Petra Hamerlik, one of the world’s experts in neuro-oncology, takes on this role alongside her post at AstraZeneca where she is a Director and Bioscience Lead in Oncology R&D, and brings with her a wealth of knowledge and expertise in brain tumour research.
Prior to her role at AstraZeneca, Professor Hamerlik was Group Leader for the Brain Tumour Biology laboratory within the Danish Cancer Research Centre and Associate Professor at the University of Copenhagen.
Among her achievements are the prestigious DFF Young Elite Scientist, Hallas-Møller Investigator and Danish Cancer Society Young Researcher Awards, which enabled her to establish an independent research line primarily focused on improving our understanding of DNA damage response regulation and its impact on genomic instability of glioblastoma brain tumours.
Her links with AstraZeneca have the potential to enhance collaboration between academic research and industry, and bring together the brightest scientific minds to tackle this deadly disease.
Funded by a grant worth £1.35 million by The Charity, Professor Hamerlik’s research will focus on the development of novel ways to treat and understand central nervous system (CNS) tumour biology, in addition to the discovery of new drug and immunotherapy treatments.
The new role supports the Manchester Cancer Research Centre’s ambition to bring together world-leading experts to tackle cancer, and we are proud to be able to support this.
Our decision to award £1.35 million of funding over the next five years demonstrates our commitment to developing new and innovative ways to improve the survival and ensure a better quality of life for those affected by a brain tumour.
Dr David Jenkinson, Chief Scientific Officer for The Brain Tumour Charity, said:
Commenting on her appointment as The Brain Tumour Charity Chair of Translational Neuro-Oncology at The University of Manchester, Professor Petra Hamerlik said: